APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC) Files An 8-K Termination of a Material Definitive Agreement

APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02.

Story continues below

APPLIED GENETIC TECHNOLOGIES CORP Exhibit
EX-99.1 2 d644374dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-linked Retinoschisis Clinical Study; Termination of Biogen Collaboration December 12,…
To view the full exhibit click here

About APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

An ad to help with our costs